Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: From bench to bedside?

Anti-Cancer Drugs

Volumn 23, Issue 8, 2012, Pages 874-882

  Trafalis, Dimitrios T ^a   Alifieris, Constantinos ^a   Dalezis, Panayiotis ^b   Geromichalos, George ^b   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

bevacizumab; clinical cases; head and neck squamous cell carcinoma; in vitro; in vivo; temsirolimus

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL; TEMSIROLIMUS;

ACUTE PANCREATITIS; ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNGEAL POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SUPRAGLOTTIC LARYNGEAL SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; SIROLIMUS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864402806     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283538c3d     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24:2606-2611. (Pubitemid 46622080)
3. Lo KW, To KF, Huang DP. Focus on nasopharyngeal cancer. Cancer Cell 2004; 5:423-428.
4. Vokes E, Weichselbaum R, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
5. Haddad R, Shin D. Recent advances in head and neck cancer. N Engl J Med 2008; 359:1143-1154.
6. Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990; 160: 405-409. (Pubitemid 20346332)
7. Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008; 20:256-263. (Pubitemid 351507544)
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
9. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-2177. (Pubitemid 46954639)
10. Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006; 28:256-269. (Pubitemid 43269893)
11. Wang F, Arun P, Friedman J, Chen Z, Waes CV. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 2009; 9:389-395.
12. Czerninski R, Amornphimoltham P, Patel V, Molinolo A, Gutkind J. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2009; 2:27-36.
13. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, et al. Innovations and challenges in renal cell carcinoma: summary statement from the second Cambridge conference. Clin Cancer Res 2007; 13: 667-670.
14. Trafalis DT, Camoutsis C, Karamanakos P, Arvanitis A, Tegou E, Ziras N, et al. Preclinical evaluation of the homo-aza-steroid ester 13beta-hydroxy- 13alpha-amino-13, 17-seco-5alpha-androstan-17-oic-13, 17-lactam-p-bis (2-chloroethyl)amino phenoxy acetate for the treatment of malignant melanoma. J BUON 2007; 8:333-339. (Pubitemid 38660085)
15. Trafalis DT, Geromichalos GD, Koukoulitsa C, Papageorgiou A, Karamanakos P, Camoutsis C. Lactandrate: a D-homo-aza-androsterone alkylator in the treatment of breast cancer. Breast Cancer Res Treat 2006; 97:17-31.
16. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601. (Pubitemid 18056527)
17. Pignon J, Le Maître A, Bourhis J. MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69:S112-S114. (Pubitemid 47369400)
18. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC. Cancer 2006; 6:28.
19. De Castro G Jr, Snitcovsky IM, Gebrim EM, Leitão GM, Nadalin W, Ferraz AR, et al. High dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2007; 264:1475-1482. (Pubitemid 350112409)
20. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2008; 45:324-334.
21. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000; 18:155-161. (Pubitemid 32165249)
22. Shang Z, Li Z, Li Jr. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vivo and in vitro studies. Int J Oral Maxillofac Surg 2006; 35:533-538.
23. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008; 28:1659-1666. (Pubitemid 351892941)
24. Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 2005; 23 (16S):5504.
25. Karamouzis M, Friedland D, Johnson R, Rajasenan K, Branstetter B, Argiris A. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis. J Clin Oncol 2007; 25 (18S):6049.
26. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Exp Opin Therap Targ 2011; 15:63-74.
27. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garćia A, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13:4964-4973. (Pubitemid 47502060)
28. Dan H, Baldwin A. Differential involvement of IkappaB kinases alpha and beta in cytokine-and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 2008; 180:7582-7589.
29. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65: 9953-9961. (Pubitemid 41541476)
30. Abraham RT. MTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004; 279:299-319.
31. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62:305-313. (Pubitemid 351692089)
32. Jimeno A, Kulesza P, Wheelhouse v, Chan A, Zhang X, Kincaid E, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007; 96:952-959. (Pubitemid 46452288)
33. UKCCCR. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1998; 58:109-113.